Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome.

[1]  T. Savarese,et al.  Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma. , 2001, The American journal of pathology.

[2]  C. Benz,et al.  Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Wiegand,et al.  Ciliary Neurotrophic Factor and Stress Stimuli Activate the Jak-STAT Pathway in Retinal Neurons and Glia , 2000, The Journal of Neuroscience.

[4]  I. Ellis,et al.  Biological and clinical associations of c‐jun activation in human breast cancer , 2000, International journal of cancer.

[5]  A. Gao,et al.  Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. , 2000, Cancer research.

[6]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[7]  R. Low,et al.  Immunohistochemical analysis of BCL-2 protein expression in renal cell carcinoma. , 1999, The Journal of urology.

[8]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[9]  Y. Matsuzawa,et al.  STAT3 mediates the survival signal in oncogenic ras‐transfected intestinal epithelial cells , 1998, International journal of cancer.

[10]  D. Carter.  TNM Classification of Malignant Tumors , 1998 .

[11]  J. Grandis,et al.  Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. , 1998, The Journal of clinical investigation.

[12]  R. Jove,et al.  Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[13]  J. Darnell.  STATs and gene regulation. , 1997, Science.

[14]  J. Blay,et al.  Role of interleukin‐6 in the paraneoplastic inflammatory syndrome associated with renal‐cell carcinoma , 1997, International journal of cancer.

[15]  R. Jove,et al.  Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells. , 1997, Cancer research.

[16]  I. Bassukas,et al.  Epidermal growth factor family and renal cell carcinoma: expression and prognostic impact. , 1997, European urology.

[17]  T. Hirano,et al.  Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. , 1996, Immunity.

[18]  K. Magnússon,et al.  Frequent expression of Bcl‐2 in renal‐cell carcinomas carrying wild‐type p53 , 1996, International journal of cancer.

[19]  G. Niehans,et al.  Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  J. Darnell,et al.  Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. , 1995, Annual review of biochemistry.

[21]  S. Akira,et al.  Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway , 1994, Cell.

[22]  J. Baselga,et al.  Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha. , 1992, Cancer research.

[23]  Masahiro Yamamoto,et al.  Interleukin‐6 (IL‐6) functions as an in vitro autocrine growth factor in renal cell carcinomas , 1989, FEBS letters.